9th Fragment-based Drug Discovery Meeting
9th RSC-BMCS Fragment-based Drug Discovery Meeting
Monday 4th – Tuesday 5th March, 2024
Hinxton Hall, Wellcome Genome Campus, Cambridge
Important links and downloads
Twitter hashtag – #Fragments24
To submit abstract, click here
The aim of the 9th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with this theme in having over three-quarters of the presentations focused on case studies. This will be complemented by technology progress in high concentration, NMR, SPR and X-ray screening.
Who should attend
This conference is suitable for scientists including chemists, biophysicists, structural biologists, etc., with either existing experience of fragments or wanting to learn about this exciting approach to drug discovery. This international meeting attracts delegates from the UK, several mainland European counties, as well as from the USA, Japan, China and South Korea.
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Call for Abstracts
Abstract submission is now open, please click here to submit your abstract. The deadline for abstract submission is Midnight (GMT), Friday 1st December 2023.
We are grateful to our confirmed sponsors for their valued support.
Emma Grant, GSK
Iva Lukac, Charnwood Molecular
Gordon Saxty, NS-MC Consulting LTD (Chair)
Marianne Schimpl, AstraZeneca
Mary Wheldon, University of Dundee (Treasurer)
Alison Woolford, Astex Pharmaceuticals
Hg3 Conferences Ltd
+44 (0)1423 529333